DCTH vs UNH

Delcath Systems remains a high-risk, high-reward investment driven by its proprietary Hepzato Kit, uniquely approved for metastatic ocular melanoma (mOM) to the liver. This strong competitive advantage and the addressing of an unmet medical need create a compelling market opportunity for future leadership and label expansion, supported by positive CHOPIN Phase 2 trial results. Q4 2025 revenue and ...

UnitedHealth Group (UNH) remains a healthcare titan, but its sheer scale and the highly regulated nature of its operations fundamentally limit its 10x growth potential within 3-5 years. The recent Optum Health operating loss of $278M in 2025 (compared to $7.77B income in 2024) is a significant concern, eroding the growth narrative that Optum once provided. Furthermore, the proposed 0.09% Medicare ...